ArticleScientific reports2026
Chitosan/β-cyclodextrin nanocarriers enhance 5-fluorouracil efficacy against colorectal cancer via pH-responsive release and apoptosis modulation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, colorectal cancer continues to be a major cause of cancer-related death. Clinical application of 5‑fluorouracil (5‑FU) is constrained by reduced bioavailability and dose‑limiting toxicity. To overcome these restrictions, a ternary drug delivery system was developed in this study. Chitosan and β‑cyclodextrin were physically assembled into a pseudopolyrotaxane complex, and 5‑FU was incorporated by solvent evaporation to form a solid dispersion. The resulting nanocomposite had a mean hydrodynamic diameter of 187 nm and a zeta potential of + 32.5 mV. Fourier transform infrared spectroscopy revealed peak shifts consistent with non‑covalent interactions. X‑ray diffraction confirmed amorphization of 5‑FU within the formulation. The ternary system released 5‑FU more rapidly at pH 5.5 than at pH 7.4. In HCT‑116 colorectal cancer cells, the 5‑FU/chitosan/β‑cyclodextrin formulation showed an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.